Actively Recruiting
A Study of TIL in Advanced Solid Tumors (DFGD)
Led by Shanghai Juncell Therapeutics · Updated on 2025-12-16
30
Participants Needed
1
Research Sites
221 weeks
Total Duration
On this page
Sponsors
S
Shanghai Juncell Therapeutics
Lead Sponsor
E
Eastern Hepatobiliary Surgery Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
CONDITIONS
Official Title
A Study of TIL in Advanced Solid Tumors (DFGD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Histologically confirmed solid tumor diagnosis
- Life expectancy greater than 3 months
- ECOG performance status of 0 to 1
- Have had tumor tissue resected and successfully produced TILs
- Failed standard treatment regimens and willing to receive TIL therapy
- At least one measurable tumor lesion
You will not qualify if you...
- Presence of other malignant tumors except those cured or inactive for at least 5 years with low recurrence risk
- Non-melanoma skin cancer, malignant lentigo, or carcinoma in situ adequately treated with no recurrence
- Need for glucocorticoid treatment with prednisone over 10 mg daily or autoimmune disease requiring immunomodulatory therapy
- Oxygen saturation below 95% at rest
- Infection with HIV, active hepatitis B or C, syphilis, or positive for related antibodies
- Significant cardiovascular abnormalities
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Third Affiliated Hospital of Naval Medical University
Shanghai, China
Actively Recruiting
Research Team
G
GC Clinical
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here